Belatacept for prevention of acute rejection in adult patients who have had a kidney transplant: an update
David Wojciechowski, Flavio VincentiKidney Transplant Service, University of California, San Francisco, CA, USAAbstract: In June 2011, the US Food and Drug Administration approved belatacept for the prophylaxis of organ rejection in adult kidney transplant recipients. This review discusses the use o...
Guardado en:
Autores principales: | Wojciechowski D, Vincenti F |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/abfcf8c1a4c946dba0610b7dfa88f69c |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Introduction to the use of belatacept: a fusion protein for the prevention of posttransplant kidney rejection
por: Ippoliti G, et al.
Publicado: (2012) -
Belatacept Use after Kidney Transplantation and Its Effects on Risk of Infection and COVID-19 Vaccine Response
por: Florian Terrec, et al.
Publicado: (2021) -
Characterizing pre-transplant and post-transplant kidney rejection risk by B cell immune repertoire sequencing
por: Silvia Pineda, et al.
Publicado: (2019) -
Anti-interleukin-2 receptor antibodies—basiliximab and daclizumab—for the prevention of acute rejection in renal transplantation
por: Junichiro Sageshima, et al.
Publicado: (2009) -
A comparison between the effect of oral and intravenous Prednisolone in prevention of acute rejection during the first two weeks of renal transplantation
por: F Oliaei, et al.
Publicado: (2005)